Company intelligence / Profile preview

Corstasis Therapeutics

Henderson, Nevada, United Statescorstasis.com ↗

Ownership: Private
Development stage: NDA

Overview

The company’s lead program, a novel nasal spray formulation of bumetanide (RSQ‑777), has completed pivotal trials. Data presented in late 2024 showed the nasal spray to be safe and effective in healthy adults and as effective as oral/IV forms in patients without heart failure or risk factors. An NDA was accepted by the FDA in November 2024 for this product.

Therapeutic areas: CardiovascularNephrology
Modalities: Small moleculeNasal spray drug deliveryDevice
Industry: Biotech

Drug pipeline

1 asset

bumetanide

NDA

Indications: Congestive heart failure, Liver disease, Kidney disease, Edema

Partnerships

TRITON FUNDS (strategic investor)

Beyond the preview

Go deeper on Corstasis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corstasis Therapeutics.

Explore the full profile